TG-2349, a Potent Protease Inhibitor, Plus Pegifn/RBV Provides Excellent Virological Responses for Harder-To-Treat Subpopulations of HCV-1B Non-Cirrhotic Patients

Authors :: C.-T. Yeh
L.-W. Chang
S.-J. Hsu
C.-M. Chen
M.-L. Yu
C.-C. Lin
P.-J. Chen
M.-Y. Chen
Y. H. Huang
M.-C. Hsu
E. Kuo
C.-H. Hung
P.-N. Cheng
C.-H.R. King
F. Sheen
Source :: Journal of Hepatology. 64:S799
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Hepatology
business.industry
Medicine
Protease inhibitor (pharmacology)
Pharmacology
business

Full Text Access

Tools